No title
Purpose: In patients with hemophilia B, treatment with extended half-life (EHL) recombi-nant factor IX allows for longer dosing intervals while providing equal or superior bleeding protection compared with standard half-life products. This enables flexible, individualized treatment schedules, which reduce the burden of prophylaxis and improve patient outcomes. This analysis compared the efficacy o
